Zavegepant

From WikiProjectMed
Jump to navigation Jump to search
Zavegepant
Zavegepant.svg
Names
Trade namesZavzpret
Other namesBHV-3500
  • N-[(2R)-3-(7-methyl-1H-indazol-5-yl)-1-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]-1-oxopropan-2-yl]-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide
Clinical data
Drug classCalcitonin gene-related peptide receptor antagonist[1]
Main usesMigraine headaches[1]
Side effectsTaste changes, nausea, sore nose, vomiting[1]
Routes of
use
Nasal
Typical dose10 mg[1]
External links
AHFS/Drugs.comMonograph
Legal
License data
Legal status
Chemical and physical data
FormulaC36H46N8O3
Molar mass638.817 g·mol−1
3D model (JSmol)
  • CC1=CC(=CC2=C1NN=C2)CC(C(=O)N3CCN(CC3)C4CCN(CC4)C)NC(=O)N5CCC(CC5)C6=CC7=CC=CC=C7NC6=O
  • InChI=1S/C36H46N8O3/c1-24-19-25(20-28-23-37-40-33(24)28)21-32(35(46)43-17-15-42(16-18-43)29-9-11-41(2)12-10-29)39-36(47)44-13-7-26(8-14-44)30-22-27-5-3-4-6-31(27)38-34(30)45/h3-6,19-20,22-23,26,29,32H,7-18,21H2,1-2H3,(H,37,40)(H,38,45)(H,39,47)/t32-/m1/s1
  • Key:JJVAPHYEOZSKJZ-JGCGQSQUSA-N
  • Key:VQDUWCSSPSOSNA-RYWNGCACSA-N

Zavegepant, sold under the brand name Zavzpret, is a medication used to treat migraine headaches.[1] It is used for the headache itself, rather than prevention.[1] It is sprayed into the nose.[1]

Common side effects include taste changes, nausea, sore nose, and vomiting.[1] Other side effects include allergic reactions.[1] Use is not recommended in people with significant liver or kidney problems.[1] Safety in pregnancy is unclear.[1] It is a calcitonin gene-related peptide receptor antagonist.[1]

Zavegepant was approved for medical use in the United States in 2023.[1] It is expected to become commercially available in July of 2023 and be priced similar to other medications in its class.[2]

Medical uses

Zavegepant is indicated for the acute treatment of migraine with or without aura in adults.[1]

Dosage

It is given at a dose of 10 mg, with at most one dose per day.[1]

Society and culture

It is sold by Pfizer.[1]

References

  1. 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 1.15 1.16 "ZAVZPRET™ (zavegepant) nasal spray" (PDF). Archived (PDF) from the original on 2023-03-11. Retrieved 2023-03-13.
  2. MSc, Nadia Stec (14 March 2023). "Zavzpret (Zavegepant) Migraine Nasal Spray from Pfizer Gets FDA Nod". Xtalks. Archived from the original on 15 March 2023. Retrieved 25 May 2023.

External links

Identifiers: